Literature DB >> 11162479

Interaction of antitumor drug, mithramycin, with chromatin.

M A Mir1, D Dasgupta.   

Abstract

Mithramycin (MTR) is an anticancer drug that blocks macromolecular biosynthesis via reversible interaction with DNA in the presence of bivalent cation such as Mg2+. Mithramycin forms two types of complexes with Mg2+: complex I (1:1 in terms of MTR:Mg2+) and complex II (2:1 in terms of MTR:Mg2+). In vivo antibiotic would interact with chromatin, a protein-DNA complex. For the first time we have demonstrated and characterized the association of both complexes of MTR with chromatin and nucleosome core. From an evaluation and comparison of the binding and thermodynamic parameters and CD spectra of bound complexes, we have shown the following. Histone(s) stand in the say of the access of the ligand(s) to chromosomal DNA. Chromatin and core particle interact differentially with the same ligand. Mode of interaction of the two complexes, I and II, with the same system is different. Significance of these results to understand the transcription inhibitory property of the drug in eukaryotic chromosome is discussed. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11162479     DOI: 10.1006/bbrc.2000.4075

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Platotex: an innovative and fully automated device for cell growth scale-up of agar-supported solid-state fermentation.

Authors:  Emilie Adelin; Noureddine Slimani; Sylvie Cortial; Isabelle Schmitz-Alfonso; Jamal Ouazzani
Journal:  J Ind Microbiol Biotechnol       Date:  2010-07-20       Impact factor: 3.346

2.  Effect of DNA groove binder distamycin A upon chromatin structure.

Authors:  Parijat Majumder; Dipak Dasgupta
Journal:  PLoS One       Date:  2011-10-26       Impact factor: 3.240

3.  Global gene expression profiling data analysis reveals key gene families and biological processes inhibited by Mithramycin in sarcoma cell lines.

Authors:  Kirti K Kulkarni; Kiran Gopinath Bankar; Rohit Nandan Shukla; Chandrima Das; Amrita Banerjee; Dipak Dasgupta; Madavan Vasudevan
Journal:  Genom Data       Date:  2014-11-08

4.  Anticancer drug mithramycin interacts with core histones: An additional mode of action of the DNA groove binder.

Authors:  Amrita Banerjee; Sulagna Sanyal; Kirti K Kulkarni; Kuladip Jana; Siddhartha Roy; Chandrima Das; Dipak Dasgupta
Journal:  FEBS Open Bio       Date:  2014-10-16       Impact factor: 2.693

5.  Transcriptional mechanism of vascular endothelial growth factor-induced expression of protein kinase CβII in chronic lymphocytic leukaemia cells.

Authors:  Ola Al-Sanabra; Andrew D Duckworth; Mark A Glenn; Benjamin R B Brown; Piera Angelillo; Kelvin Lee; John Herbert; Francesco Falciani; Nagesh Kalakonda; Joseph R Slupsky
Journal:  Sci Rep       Date:  2017-02-24       Impact factor: 4.379

6.  Differential Impact of Random GC Tetrad Binding and Chromatin Events on Transcriptional Inhibition by Olivomycin A.

Authors:  Alexandra K Isagulieva; Dmitry N Kaluzhny; Artemy D Beniaminov; Nataliya V Soshnikova; Alexander A Shtil
Journal:  Int J Mol Sci       Date:  2022-08-09       Impact factor: 6.208

7.  Mithramycin targets sp1 and the androgen receptor transcription level-potential therapeutic role in advanced prostate cancer.

Authors:  Long G Wang; Anna C Ferrari
Journal:  Transl Oncogenomics       Date:  2006-10-11

8.  The DNA intercalators ethidium bromide and propidium iodide also bind to core histones.

Authors:  Amrita Banerjee; Parijat Majumder; Sulagna Sanyal; Jasdeep Singh; Kuladip Jana; Chandrima Das; Dipak Dasgupta
Journal:  FEBS Open Bio       Date:  2014-02-15       Impact factor: 2.693

Review 9.  Chromatin as a target for the DNA-binding anticancer drugs.

Authors:  Parijat Majumder; Suman K Pradhan; Pukhrambam Grihanjali Devi; Sudipta Pal; Dipak Dasgupta
Journal:  Subcell Biochem       Date:  2007
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.